drugset

drugset / Trial / NCT02381886

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

NCT02381886 ↗

Phase 1 Active not recruiting 166 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.

Timeline

Start: 2015-03-06
Primary completion: 2016-12-07
Completion: 2030-10-31

Publications

DiNardo CD, Hochhaus A, Frattini MG, Yee K, Zander T, Kramer A, Chen X, Ji Y, Parikh NS, Choi J, Wei AH. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol. 2023 Mar;149(3):1145-1158. doi: 10.1007/s00432-022-03983-6. Epub 2022 Mar 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IDH305	Small molecule	—	Oral

Indications

No indication recorded.